Gefitinib is a targeted cancer drug, specifically an oral, small molecular tyrosine kinase inhibitor of the epidermal growth factor receptor, primarily used in the treatment of NSCLC with activating EGFR mutations [22]. Here, EGFR is linked to non-small cell lung carcinoma.